Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients.

This publication has 14 references indexed in Scilit:

• p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
  Journal of Clinical Oncology, 2000
• The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
  Annals of Oncology, 2000
• Routine Analysis of p53 Mutation in Clinical Breast Tumor Specimens Using Fluorescence–Based Polymerase Chain Reaction and Single Strand Conformation Polymorphism
  Diagnostic Molecular Pathology, 2000
• Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
  British Journal of Cancer, 1999
• Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
  European Journal Of Cancer, 1999
• Prognosis and prediction of response in breast cancer: the current role of the main biological markers
  Cell Proliferation, 1998
• Meta-analyses, multivariate analyses, and coping with the play of chance
  The Lancet, 1998
• Detection ofp53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer
  International Journal of Cancer, 1997
• Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
  Nature Medicine, 1996
• Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
  Nature Medicine, 1995